Michael Arenberg - Dec 27, 2022 Form 4 Insider Report for Imago BioSciences, Inc. (IMGO)

Role
Officer
Signature
/s/ Hugh Rienhoff, as Attorney-in-fact for Michael Arenberg
Stock symbol
IMGO
Transactions as of
Dec 27, 2022
Transactions value $
-$865,888
Form type
4
Date filed
12/29/2022, 03:06 PM
Previous filing
Dec 20, 2022
Next filing
Jan 5, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IMGO Common Stock Options Exercise $436K +28.2K +113.3% $15.45 53.1K Dec 27, 2022 Direct
transaction IMGO Common Stock Options Exercise $1.23M +66.8K +125.79% $18.44 120K Dec 27, 2022 Direct
transaction IMGO Common Stock Sale -$2.53M -70.5K -58.81% $35.93 49.4K Dec 27, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -28.2K -92.92% $0.00 2.15K Dec 27, 2022 Common Stock 28.2K $15.45 Direct
transaction IMGO Stock Option (Right to Buy) Options Exercise $0 -66.8K -18% $0.00 304K Dec 27, 2022 Common Stock 66.8K $18.44 Direct
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transaction was executed in multiple trades in prices ranging from $35.93 to $35.935, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

Remarks:

Chief Operating and Business Officer On November 19, 2022, the Issuer entered into an Agreement and Plan of Merger, by and among the Issuer, Merck Sharpe & Dohme LLC and M-Inspire Merger Sub, Inc., providing for the merger of M-Inspire Merger Sub, Inc. with and into the Issuer (the "Merger"), with the Issuer surviving as a wholly owned subsidiary of Merck Sharpe & Dohme LLC. In connection with the Merger, to mitigate the potential impact of Section 280G and Section 4999 of the Internal Revenue Code of 1986, as amended, the Issuer accelerated the exercisability of the reported stock options and vested a portion, allowing the Reporting Person to enter into the transactions disclosed on this Form 4.